ROCKVILLE, Md., March 22, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its fourth quarter and full year 2022 financial results after the close of the U.S. financial markets on Wednesday, March 29th, 2023. OpGen’s management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide an update on business activities.
| Conference Call Details | ||
| U.S. Dial-in Number: | 1-877-704-4453 | |
| International Dial-in Number: | 1-201-389-0920 | |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1595064&tp_key=d21054e901 | |
| Conference ID: | 13735798 | |
| Replay Details | ||
| U.S. Dial-in Number: International Dial-in Number: Replay PIN: | 1-844-512-2921 1-412-317-6671 13735798 | |
Following the conclusion of the conference call, a replay will be available through April 12, 2023. The live, listen-only webcast of the conference call may also be accessed by visiting the Investors section of the Company’s website at www.opgen.com. A replay of the webcast will be available following the conclusion of the call and will be archived on the Company’s website under Financials & Filings.
About OpGen, Inc.
OpGen, Inc. (Rockville, MD, U.S.A.) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s current product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction including ARESiss, ARESid, and AREScloud, as well as the Curetis CE-IVD-marked PCR-based SARS-CoV-2 test kit.
For more information, please visit www.opgen.com.
OpGen:
Oliver Schacht
President and CEO
This email address is being protected from spambots. You need JavaScript enabled to view it.
OpGen Investor & Press Contact:
Alyssa Factor
Edison Group
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.60 |
| Daily Change: | -1.30 -68.53 |
| Daily Volume: | 3,912 |
| Market Cap: | US$6.020M |
October 12, 2023 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
